Future perspectives and outstanding questions Despite substantial progress, several unmet needs and key questions require investigation to fully realize the therapeutic potential of GLP-1-based therapies in MASLD/MASH
Between manufacturer programs, new cash-pay pricing, and compounded alternatives, most patients can now access semaglutide treatment at affordable prices
This move aims to address the high rate of overweight and obesity in the UK and the existing challenges in accessing weight management care, particularly GLP-1 treatments, through the NHS and private sectors
Semaglutide studies show that lean mass loss typically accounts for 26% to 40% of total weight lost
SeekPeptides has analyzed every available clinical dataset to give you the most comprehensive breakdown available anywhere
[2] [3] This multifaceted mechanism helps improve glycaemic control in people with type 2 diabetes whilst also facilitating weight loss